Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (257)
NICE advice (26)
Quality standard (13)
Guidance programme
Guidance programme
Cancer service guidelines (5)
Clinical guidelines (17)
Diagnostics guidance (11)
Health technology evaluations (1)
Interventional procedures guidance (44)
Medical technologies guidance (3)
NICE guidelines (23)
Public health guidelines (1)
Social care guidelines (2)
Technology appraisal guidance (175)
Apply filters
Showing 1 to 50 of 257
Sort by
Date
Title
Apply sorting
cancer
Remove cancer filter
Type: Guidance
Remove Type: Guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast
cancer
DG58
9 May 2024
9 May 2024
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract
cancer
(terminated appraisal)
TA966
24 April 2024
24 April 2024
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial
cancer
with high microsatellite instability or mismatch repair deficiency
TA963
3 April 2024
3 April 2024
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin
cancer
IPG784
2 April 2024
2 April 2024
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal
cancer
after response to first-line platinum-based chemotherapy
TA962
28 March 2024
28 March 2024
Ovarian
cancer
: identifying and managing familial and genetic risk
NG241
21 March 2024
21 March 2024
Lung
cancer
: diagnosis and management
NG122
28 March 2019
8 March 2024
Talazoparib for treating HER2-negative advanced breast
cancer
with germline BRCA mutations
TA952
21 February 2024
21 February 2024
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate
cancer
TA951
7 February 2024
7 February 2024
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal
cancer
TA946
17 January 2024
17 January 2024
Early and locally advanced breast
cancer
: diagnosis and management
NG101
18 July 2018
16 January 2024
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract
cancer
TA944
10 January 2024
10 January 2024
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical
cancer
TA939
13 December 2023
13 December 2023
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate
cancer
after 2 or more treatments
TA930
15 November 2023
15 November 2023
Familial breast
cancer
: classification, care and managing breast
cancer
and related risks in people with a family history of breast
cancer
CG164
25 June 2013
14 November 2023
Cabozantinib for previously treated advanced differentiated thyroid
cancer
unsuitable for or refractory to radioactive iodine
TA928
1 November 2023
1 November 2023
Ovarian
cancer
: recognition and initial management
CG122
27 April 2011
2 October 2023
Suspected
cancer
: recognition and referral
NG12
23 June 2015
2 October 2023
Artificial intelligence-derived software to analyse chest X-rays for suspected lung
cancer
in primary care referrals: early value assessment
HTE12
28 September 2023
28 September 2023
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine
cancer
with high microsatellite instability or mismatch repair deficiency
TA914
20 September 2023
20 September 2023
Quantitative faecal immunochemical testing to guide colorectal
cancer
pathway referral in primary care
DG56
24 August 2023
24 August 2023
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung
cancer
TA911
26 July 2023
26 July 2023
Lorlatinib for untreated ALK-positive advanced non-small-cell lung
cancer
TA909
12 July 2023
12 July 2023
Irreversible electroporation for treating prostate
cancer
IPG768
5 July 2023
5 July 2023
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal
cancer
after 2 or more courses of platinum-based chemotherapy
TA908
5 July 2023
5 July 2023
Oesophago-gastric
cancer
: assessment and management in adults
NG83
24 January 2018
4 July 2023
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate
cancer
TA903
21 June 2023
21 June 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial
cancer
TA904
21 June 2023
21 June 2023
Cemiplimab for treating recurrent or metastatic cervical
cancer
(terminated appraisal)
TA901
20 June 2023
20 June 2023
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung
cancer
TA898
14 June 2023
14 June 2023
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal
cancer
IPG763
6 June 2023
6 June 2023
Transperineal biopsy for diagnosing prostate
cancer
DG54
1 June 2023
1 June 2023
MRI fusion biopsy systems for diagnosing prostate
cancer
DG53
24 May 2023
24 May 2023
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast
cancer
after chemotherapy
TA886
10 May 2023
10 May 2023
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate
cancer
TA887
10 May 2023
10 May 2023
Capmatinib for treating advanced non-small-cell lung
cancer
with MET exon 14 skipping (terminated appraisal)
TA884
3 May 2023
3 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction
cancer
after anti-HER2 treatment (terminated appraisal)
TA879
6 April 2023
6 April 2023
Focal therapy using high-intensity focused ultrasound for localised prostate
cancer
IPG756
5 April 2023
5 April 2023
Maximal cytoreductive surgery for advanced ovarian
cancer
IPG757
5 April 2023
5 April 2023
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung
cancer
TA876
22 March 2023
22 March 2023
Regorafenib for previously treated metastatic colorectal
cancer
TA866
8 February 2023
8 February 2023
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate
cancer
IPG752
7 February 2023
7 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast
cancer
after 1 or more anti-HER2 treatments
TA862
1 February 2023
1 February 2023
Thyroid
cancer
: assessment and management
NG230
19 December 2022
19 December 2022
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung
cancer
after platinum-based chemotherapy
TA850
14 December 2022
14 December 2022
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast
cancer
TA851
14 December 2022
14 December 2022
Trifluridine–tipiracil for treating metastatic gastric
cancer
or gastro-oesophageal junction adenocarcinoma after 2 or more treatments
TA852
14 December 2022
14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung
cancer
(terminated appraisal)
TA848
1 December 2022
1 December 2022
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast
cancer
after endocrine therapy
TA836
26 October 2022
26 October 2022
Magtrace and Sentimag system for locating sentinel lymph nodes for breast
cancer
MTG72
5 October 2022
5 October 2022
Current page
1
2
3
4
5
6
Page
1
of
6
Next page
Results per page
10
25
50
All
Back to top